CN117915956A - M6pr细胞表面受体结合化合物和缀合物 - Google Patents

M6pr细胞表面受体结合化合物和缀合物 Download PDF

Info

Publication number
CN117915956A
CN117915956A CN202280060559.6A CN202280060559A CN117915956A CN 117915956 A CN117915956 A CN 117915956A CN 202280060559 A CN202280060559 A CN 202280060559A CN 117915956 A CN117915956 A CN 117915956A
Authority
CN
China
Prior art keywords
compound
optionally substituted
conjugate
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280060559.6A
Other languages
English (en)
Chinese (zh)
Inventor
B·B·布施
J·T·恩斯特
G·K·帕卡德
J·G·路易斯
E·D·图尔托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Licia Therapeutics
Original Assignee
Licia Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licia Therapeutics filed Critical Licia Therapeutics
Publication of CN117915956A publication Critical patent/CN117915956A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280060559.6A 2021-07-14 2022-07-14 M6pr细胞表面受体结合化合物和缀合物 Pending CN117915956A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221915P 2021-07-14 2021-07-14
US63/221,915 2021-07-14
PCT/US2022/037196 WO2023288015A1 (en) 2021-07-14 2022-07-14 M6pr cell surface receptor binding compounds and conjugates

Publications (1)

Publication Number Publication Date
CN117915956A true CN117915956A (zh) 2024-04-19

Family

ID=82786881

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280060559.6A Pending CN117915956A (zh) 2021-07-14 2022-07-14 M6pr细胞表面受体结合化合物和缀合物

Country Status (7)

Country Link
US (1) US20240335544A1 (https=)
EP (1) EP4370156A1 (https=)
JP (1) JP2024524613A (https=)
CN (1) CN117915956A (https=)
AU (1) AU2022310346A1 (https=)
CA (1) CA3226268A1 (https=)
WO (1) WO2023288015A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12258332B2 (en) 2021-07-14 2025-03-25 Lycia Therapeutics, Inc. ASGPR cell surface receptor binding compounds and conjugates

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026503462A (ja) 2023-01-18 2026-01-29 ライシア セラピューティクス， インコーポレイテッド 自己抗体の分解のためのリソソーム標的化二官能性分子
CN120835794A (zh) * 2023-01-18 2025-10-24 利西亚治疗公司 M6pr结合化合物和缀合物
CN120882430A (zh) 2023-01-18 2025-10-31 利西亚治疗公司 循环溶酶体靶向抗体缀合物
WO2024182772A2 (en) * 2023-03-02 2024-09-06 Avilar Therapeutics, Inc. Mannose 6-phosphate receptor binding compounds for the degradation of extracellular proteins
FR3149188A1 (fr) * 2023-05-31 2024-12-06 Nanomedsyn Pro-ligands, conjugués comprenant lesdits pro-ligands et leurs utilisations pour des applications thérapeutiques
CN121548590A (zh) * 2023-07-25 2026-02-17 深圳湾实验室 一种多特异性结合蛋白及其应用
WO2026015664A1 (en) 2024-07-10 2026-01-15 Lycia Therapeutics, Inc. Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
WO2015143091A1 (en) 2014-03-19 2015-09-24 Genzyme Corporation Site-specific glycoengineering of targeting moieties
CA3205824A1 (en) 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
FR3041345B1 (fr) * 2015-09-18 2019-06-14 Nanomedsyn Composes polysaccharides multi-fonctionnalises et leur utilisation pour cibler le recepteur du mannose 6-phosphate cation-independant
AU2019404061A1 (en) 2018-12-19 2021-07-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules for lysosomal targeting and related compositions and methods
US20230051872A1 (en) 2019-03-22 2023-02-16 Reflexion Pharmaceuticals, Inc. Multivalent D-Peptidic Compounds for Target Proteins
KR20220044612A (ko) 2019-03-22 2022-04-08 리플렉시온 파마슈티컬스, 인크. Vegf에 대한 d-펩티드성 화합물
US20230158155A1 (en) 2020-01-10 2023-05-25 Lycia Therapeutics, Inc. Cell Surface Receptor Binding Compounds and Conjugates
EP4171658A4 (en) * 2020-06-24 2025-04-09 Lycia Therapeutics, Inc. Modified viral compositions for viral transduction
EP4171659A4 (en) * 2020-06-24 2025-04-09 Lycia Therapeutics, Inc. BIFUNCTIONAL BRIDGE COMPOSITIONS FOR VIRAL TRANSDUCTION

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12258332B2 (en) 2021-07-14 2025-03-25 Lycia Therapeutics, Inc. ASGPR cell surface receptor binding compounds and conjugates

Also Published As

Publication number Publication date
JP2024524613A (ja) 2024-07-05
US20240335544A1 (en) 2024-10-10
CA3226268A1 (en) 2023-01-19
EP4370156A1 (en) 2024-05-22
WO2023288015A1 (en) 2023-01-19
AU2022310346A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
CN117915956A (zh) M6pr细胞表面受体结合化合物和缀合物
US12258332B2 (en) ASGPR cell surface receptor binding compounds and conjugates
US20230158155A1 (en) Cell Surface Receptor Binding Compounds and Conjugates
US12311030B2 (en) Antibody-sting agonist conjugates and their use in immunotherapy
US20210332080A1 (en) Hydrophilic linkers for antibody drug conjugates
IL269283B2 (en) Benzazepine compounds, conjugates and uses thereof
JP2024506300A (ja) 免疫刺激化合物及びコンジュゲート体
JP2026503463A (ja) Ａｓｇｐｒ結合化合物およびコンジュゲート
CN120835794A (zh) M6pr结合化合物和缀合物
CN120882430A (zh) 循环溶酶体靶向抗体缀合物
TW202406574A (zh) 一種包含親水性糖結構的配體-藥物偶聯物
CN120752059A (zh) 用于adc缀合的拓扑异构酶i抑制剂的前药及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination